Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 3 November 1967:
Vol. 158. no. 3801, pp. 669 - 670
DOI: 10.1126/science.158.3801.669
Prev | Table of Contents | Next

Articles

2,5-Dimethoxy-4-methyl-amphetamine (STP): A New Hallucinogenic Drug

Solomon H. Snyder 1, Louis Faillace 1, and Leo Hollister 2

1 Departments of Pharmacology and Psychiatry, Johns Hopkins University School of Medicine, Baltimore, Maryland 21205
2 Veterans Administration Hospital, Palo Alto, California 94304

We have assessed the effects in normal control volunteers of 2,5-dimethoxy-4-methyl-amphetamine, the chemical present in the hallucinogenic drug STP, in two independent trials. In low doses, this compound produces a mild euphoria. Doses greater than 3 milligrams may cause pronounced hallucinogenic effects lasting about 8 hours and similar to those produced by hallucinogenic doses of lysergic acid diethylamide, mescaline, and psilocybin. 2,5-Dimethoxy-4-methyl-amphetamine, which is chemically related to mescaline and amphetamine, is about 100 times more potent as a hallucinogen than mescaline and only one-thirtieth as potent as lysergic acid diethylamide. Its psychological effects are not accentuated by chlorpromazine.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Role of the Serotonin 5-HT2A Receptor in Learning.
J. A. Harvey (2003)
Learn. Mem. 10, 355-362
   Abstract »    Full Text »    PDF »
Dose-Response Study of N,N-Dimethyltryptamine in Humans: I. Neuroendocrine, Autonomic, and Cardiovascular Effects.
R. J. Strassman and C. R. Qualls (1994)
Arch Gen Psychiatry 51, 85-97
   Abstract »    PDF »
Stereospecific Actions of DOET (2,5-Dimethoxy-4-Ethylamphetamine) in Man.
S. H. Snyder, S. Unger, R. Blatchley, and C. F. Barfknecht (1974)
Arch Gen Psychiatry 31, 103-106
   Abstract »    PDF »
DOET(2,5-Dimethoxy-4-Ethylamphetamine), a New Psychotropic Drug: Effects of Varying Doses in Man.
S. H. Snyder, H. Weingartner, and L. A. Faillace (1971)
Arch Gen Psychiatry 24, 50-55
   Abstract »    PDF »
Management of "Bad Trips" in an Evolving Drug Scene.
R. L. Taylor, J. I. Maurer, and J. R. Tinklenberg (1970)
JAMA 213, 422-425
   Abstract »    PDF »
Evaluation and Treatment of the Suspected Drug User in the Emergency Room.
G. G. Dimijian and F. A. Radelat (1970)
Arch Intern Med 125, 162-170
   Abstract »    PDF »
A New Psychotropic Agent.
S. H. Snyder, L. A. Faillace, and H. Weingartner (1969)
Arch Gen Psychiatry 21, 95-101
   Abstract »    PDF »
Relation of Pharmacological and Behavioral Effects of a Hallucinogenic Amphetamine to Distribution in Cat Brain.
J. E. Idanpaan-Heikkila, W. M. McIsaac, B. T. Ho, G. E. Fritchie, and L. W. Tansey (1969)
Science 164, 1085-1087
   Abstract »    PDF »
Hallucinogen-Tranquilizer Interaction: Its Nature.
M. F. Halasz, J. Formanek, and A. S. Marrazzi (1969)
Science 164, 569-571
   Abstract »    PDF »
Medical Complications of Pleasure-Giving Drugs.
D. B. Louria (1969)
Arch Intern Med 123, 82-87
   Abstract »    PDF »
Implications for Research.
D. X. Freedman (1968)
JAMA 206, 1280-1284
   Abstract »    PDF »
2,5-Dimethoxy-4-Methyl-Amphetamine: New Hallucinogenic Drug.
P. A. Cabe, S. H. Snyder, L. Faillace, and L. Hollister (1968)
Science 159, 1491-1492
   PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)